A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05514873` - An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors	Phase 3
Completed	`NCT04124965` - A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis	Phase 3
Recruiting	`NCT04833894` - Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis	Phase 2/Phase 3
Active, not recruiting	`NCT02950155` - A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis	Phase 3
Completed	`NCT03315130` - Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis	Phase 2
Recruiting	`NCT05556096` - Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	Phase 3
Not yet recruiting	`NCT06149559` - A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis	Phase 2/Phase 3
Completed	`NCT03920293` - Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis	Phase 3
Not yet recruiting	`NCT06193889` - A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis	Phase 2
Completed	`NCT03770403` - A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.	Phase 3
Completed	`NCT03971422` - A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis	Phase 3
Recruiting	`NCT05403541` - Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis	Phase 3
Recruiting	`NCT05644561` - Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)	Phase 3
Completed	`NCT00515450` - Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis	Phase 3
Recruiting	`NCT06064695` - Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis	N/A
Withdrawn	`NCT04982289` - Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis	Phase 2
Completed	`NCT04735432` - Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis	Phase 3
Completed	`NCT04650854` - A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis	Phase 3
Active, not recruiting	`NCT05218096` - Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis	Phase 2
Active, not recruiting	`NCT04225871` - Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis	Phase 3

NCT number	NCT04963270
Study type	Interventional
Source	Hoffmann-La Roche
Contact	Reference Study ID Number: GE42063 https://forpatients.roche.com
Phone	888-662-6728 (U.S.)
Email	global-roche-genentech-trials@gene.com
Status	Recruiting
Phase	Phase 3
Start date	October 19, 2021
Completion date	September 19, 2024

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms